Epidemiology

Physics

Internal medicine

Pathology

Sociology

Rate ratio

Pediatrics

Kenya

Streptococcus pneumoniae

Population

Bacteria

Incidence (geometry)

Biology

Optics

Demography

Political science

Vaccination

Immunology

Pneumococcal conjugate vaccine

Pneumococcal disease

Carriage

Genetics

Medicine

Environmental health

The Lancet

Ten-valent pneumococcal conjugate vaccine (PCV10), delivered at 6, 10, and 14 weeks of age was introduced in Kenya in January, 2011, accompanied by a catch-up campaign in Kilifi County for children aged younger than 5 years. Coverage with at least two PCV10 doses in children aged 2-11 months was 80% in 2011 and 84% in 2016; coverage with at least one dose in children aged 12-59 months was 66% in 2011 and 87% in 2016. We aimed to assess PCV10 effect against nasopharyngeal carriage and invasive pneumococcal disease (IPD) in children and adults in Kilifi County.

Effect of ten-valent pneumococcal conjugate vaccine on invasive pneumococcal disease and nasopharyngeal carriage in Kenya: a longitudinal surveillance study